According to these findings, we proposed that ERK1/2 and p38 signaling contributes to complex regulatory mechanisms in HNSCC, and these responses and further detailed mechanisms should be elucidated before the clinical application of 6-shogaol in HNSCC therapy. Here, MAPK3 is linked to head and neck squamous cell carcinoma.